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ABSTRACT 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
Lactobacillus containing probiotics improve symptoms of gas production in patients with lactose 
intolerance and lactose maldigestion. 
 
STUDY DESIGN: A systematic review of two randomized, double-blind, placebo controlled, 
crossover trials (RCTs) and one case series. Each article was published in English after 2010. 
 
DATA SOURCES: Articles were obtained through PubMed and Cochrane Library databases. 
All articles were published in peer-reviewed journals and selected for their relevance to the 
clinical question. 
 
OUTCOMES MEASURED: Patient perception of gas production, defined as flatulence and 
distention or bloating, was measured in each study. Pakdaman et al. (Nutr J. 2016;15(1):56. doi: 
10.1186/s12937-016-0172-y) measured flatulence through a 6-hour symptom score requiring 
patients to rank the symptom on a scale from 0 (no symptoms) to 10 (most severe symptoms). 
Vitellio et al. (Nutrients. 2019;11(4):886. doi: 10.3390/nu11040886) measured intensity of 
bloating by a visual analog scale (VAS), which ranged from 0 mm (no perception) to 100 mm 
(worst possible perception). Almeida et al. (Nutr Clin Pract. 2012;27(2):247-251. doi: 
10.1177/0884533612440289) measured flatulence and distension together using this scale 0 = 
none, 1 = mild, 2 = moderate, and 3 = severe. 
 
RESULTS: The double-blinded RCT by Pakdaman et al. (Nutr J. 2016;15(1):56. doi: 
10.1186/s12937-016-0172-y) did not find a statistically significant decrease in flatulence 
between the treatment and placebo groups (p = 0.770). The flatulence score in the treatment 
group was 3.16 and 3.21 in the placebo group. Conversely, the double-blinded RCT by Vitellio 
et al. (Nutrients. 2019;11(4):886. doi: 10.3390/nu11040886) found a reduction in bloating that 
was statistically significant between the treatment and placebo groups (p = 0.028). The VAS 
score was 60 for the treatment group and 77 for the placebo group. Finally, the case-series 
conducted by Almeida et al. (Nutr Clin Pract. 2012;27(2):247-251. doi: 
10.1177/0884533612440289) found a small decrease in patient reported flatulence and 
distension with a mean change of 0.4. However, this change was not found to be statistically 
significant (p > 0.05). 
 
CONCLUSION: Patients reported a reduction in symptoms of gas production in all studies but 
the treatment effects were small with the only statistically significant difference seen in Vitellio 
et al. (Nutrients. 2019;11(4):886. doi: 10.3390/nu11040886). Because of these small treatment 
effects and lack of statistical significance, the evidence is inconclusive for the efficacy of 
Lactobacillus at improving symptoms of gas production. Future studies should include larger 
sample sizes and longer treatment periods with uniform symptomatic measurement across 
studies. 
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INTRODUCTION:  
Lactose maldigestion (LM) is due to insufficient lactase activity, which inhibits the body 
from properly digesting lactose.1 Lactose malabsorption occurs when non-hydrolyzed lactose 
proceeds through the intestines as a result of inadequate lactase activity, leading to an inability to 
absorb the lactose.2 Lactose intolerance (LI) occurs when a person has lactose malabsorption or 
LM in addition to gastrointestinal symptoms.1, 2 The most common symptoms of LI include 
abdominal pain, bloating, flatulence, and diarrhea.3 Lactose malabsorption has been found to 
affect 68% of the world population with 42% of the North American population being affected.2 
However, these percentages likely underestimate the number of individuals affected by LI, as it 
has been reported that under 20% of those experiencing gastrointestinal symptoms of bloating, 
diarrhea, and abdominal pain will seek medical attention and treatment.4  Because these are three 
of the four most common LI symptoms, this demonstrates that the number of individuals affected 
by LI go largely unreported and undiagnosed. 
Given the number of LI cases that go undiagnosed, it is important for providers to inquire 
about the common gastrointestinal symptoms patients may experience and recognize individuals 
with this condition so that they may receive proper treatment. With the projected shortage of 
physicians, advanced practice providers are expected to become increasingly important in 
meeting the healthcare needs of patients.5 This means that physician assistants (PAs) are at the 
forefront of patient care and are integral in diagnosing and treating patients with gastrointestinal 
diseases. The number of visits for LI specifically has not yet been evaluated. However, digestive 
tract diseases are responsible for 105 million ambulatory care visits each year in the United 
States and LI often resembles the symptoms of other functional gastrointestinal disorders. 4, 6 
Furthermore, the annual healthcare cost associated with LI has not been identified but digestive 
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diseases have been reported to cost $142 billion annually.4 Additionally, patients may purchase 
Lactaid, which is an exogenous supplement for lactase that can be administered before lactose 
ingestion and costs patients $0.24 per fast acting tablet.3 
Lactaid tablets attempts to replace lactase because LI is typically the result of declining levels 
of the lactase enzyme.3 There is a natural physiological decline in the activity of lactase after 
birth.7 However, some individuals experience a greater decline than others.7 Lactase functions to 
hydrolyze lactose, which allows it to be absorbed in intestines.3 With inadequate lactase activity, 
the body is unable to digest lactose as it continues through the gastrointestinal tract.7 This leads 
to an increased osmotic load in the colon causing the common symptoms of LI listed above.3, 7 
However, these symptoms typically do not occur until lactase activity is reduced by half, which 
helps explain why not all patients experience symptoms despite a decline in lactase after 
infancy.8 
For treatment of LI, patients are often advised to maintain a low-milk or dairy free diet to 
avoid causing symptoms.3 These patients are instructed to consume no more than a cup of milk 
or 12g of lactose per day, as this has been associated with little to no symptom precipitation.3 
However, avoiding dairy products deprives patients of the nutrients these products offer such as 
calcium, vitamin D, potassium, and B vitamins.7 Other treatment options include exogenous 
lactase supplementation, with the most notable brand being Lactaid tablets.3 This supplement 
allows patients to consume milk products and provides lactase enzyme to aid in lactose 
digestion. However, studies have not shown these supplements to be significantly efficacious. 3 
Alternatively, probiotic supplementation aims to alter the gut flora by increasing lactic acid 
bacteria, such as Lactobacillus, and enabling the patient to digest lactose with less symptoms.3, 7 
This allows patients to continue ingesting dairy products and obtain the associated nutrients 
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without having gastrointestinal discomfort. This paper evaluates two randomized, double-blind, 
placebo-controlled, crossover trials and one case series comparing the efficacy of Lactobacillus 
containing probiotics in reducing LI and LM symptoms. 
OBJECTIVE:  
The objective of this selective evidence based medicine review is to determine whether or 
not Lactobacillus containing probiotics improve symptoms of gas production in patients with 
lactose intolerance and lactose maldigestion. 
METHODS:  
 Articles were selected for this review utilizing Cochrane Library and PubMed databases. 
Searches in these databases were conducted using the keywords “lactose intolerance,” 
“Lactobacillus,” and “probiotic.” Articles were then selected for their relevance to the clinical 
question and the inclusion of patient-oriented outcomes. Inclusion criteria consisted of primary 
research and articles published after 2010. Exclusion criteria included studies published in or 
before 2010 and studies including patients under the age of 18.  
 The studies selected include two randomized, double-blind, placeb- controlled, crossover 
trials and one case series. All articles were published in English and included published data. The 
population of interest in these articles was patients over 18 years of age with symptomatic LI or 
LM. Both the Pakdaman et al. and Vitellio et al. studies are randomized trials that compare the 
efficacy of a Lactobacillus containing probiotics to a placebo in symptomatic improvement.6, 7 
The Almeida et al. study is a case series that compared patients’ symptoms after administration 
of a Lactobacillus containing probiotic to the patients’ baseline symptoms.1 The statistics utilized 
from these studies include mean change from baseline and p-values. Table 1 demonstrates 
further inclusion and exclusion criteria for the individual studies in this review. 
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Table 1: Demographics & Characteristics of included studies 
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 The primary outcome measured in this review was gas production through patient 
reported bloating, distension and flatulence after lactose ingestion. These outcomes were 
assessed differently in each study. The study by Pakdaman et al. measured flatulence through a 
6-hour symptom score, which required patients to rank symptoms at baseline and after lactose 
ingestion on a scale of 0 (no symptoms) to 10 (most severe symptoms).7 These baseline score 
was subsequently subtracted from the lactose challenge score to provide each patients’ symptom 
score.7 The Vitellio et al. article measured change from baseline in intensity of bloating after 
taking either the placebo or probiotic packet through a visual analog scale (VAS) with a range of 
0 mm to 100 mm.6 The VAS scale required patients to place a mark along a horizontal line with 
0 at one end indicating the patient has “no perception” of that symptom and 100 at the other end 
indicating that the patient has the “worst possible perception” of the symptom.6 The final article 
by Almeida et al. observed flatulence and distension together by having patients classify the 
intensity of their symptom using the following scale; 0 = none, 1 = mild, 2 = moderate, and 3 = 
severe.1 These patients were assessed before and after a lactose challenge test both at baseline 
and after 4 weeks of probiotic treatment.1 
RESULTS:  
 Pakdaman et al. (2016) conducted a randomized, double-blind, placebo-controlled, 
crossover trial comparing the effects of a capsule containing the probiotic DDS-1 strain of 
Lactobacillus acidophilus compared to a placebo capsule.7 A total of 126 patients were recruited 
through online advertisement.7 A total of 38 patients were ultimately chosen for the study based 
on the criteria of being between age 18-75 years old with a 6-hour symptom score of 10 or more 
during a clinical lactose challenge test and without GI illnesses such as ulcerative colitis (UC) 
and Crohn’s disease.7 Additional inclusion and exclusion criteria are outlined in Table 1. After 
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selection for the study, patients were randomized into the placebo and DDS-1 experimental 
groups through numbered envelopes to ensure blinding of researchers.7 Initially, 20 patients were 
placed into the treatment group and 18 patients were placed into the placebo group.7 Patients 
took the product they were assigned, either placebo or DDS-1 capsules which were placed in 
identical packaging and identical capsules, for a total of 4 weeks.7 Patients were reevaluated at 4 
weeks, undergoing a lactose challenge test and reporting their 6-hour symptom scores.7 Patients 
then underwent a washout period of 2 weeks before entering the crossover period of the study, 
where participants received the capsule that they did not receive during the first leg of the study.7  
Fifteen subjects failed to complete the initial 4 weeks of the study due to relocation, loss 
to follow up, or withdrawal.7 At the conclusion of the study, 22 participants completed both legs 
of the crossover trial.7 The mean change from baseline in patient reported flatulence score after 
receiving the DDS-1 capsule was reported as 3.16 ± 2.87 after 4 weeks of treatment (Table 2).7 
The mean change from baseline in patient reported flatulence score after receiving the placebo 
capsule was reported as 3.21 ± 2.70 after 4 weeks of treatment (Table 2).7 Although there is 
slight decrease in flatulence reported by the DDS-1 experimental group, researchers report no 
significant difference in the symptom score between the experimental and control groups, as p = 
0.770 (Table 2).7 Patients were screened for adverse events at each evaluation and none were 
reported during the study.7 This article did not discuss tolerability or patient compliance. 
Table 2 – 6-hr symptom score expressed as mean ± SD for control and experimental groups.7 
 Mean Change from Baseline P-value 
Experimental Group 3.16 ± 2.87 0.770 
Control Group 3.21 ± 2.70 
* = Statistically significant (P < 0.05) 
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 The Vitellio et al. study is a randomized, double-blind, placebo-controlled, crossover trial 
comparing the effects of Zircombi (ZR), a probiotic mixture of Bifidobacterium longum and 
Lactobacillus rhamnosus, with a placebo (PL).6 An initial group of 135 symptomatic patients 
were screened.6 Patients were excluded if they had other gastrointestinal diseases such as UC and 
Crohn’s, pregnant individuals, and those with recent abdominal surgeries.6 Additionally, patients 
underwent hydrogen (H2) breath testing, which is diagnostic of LI.6 Only those with positive H2 
tests were considered for the study and a final cohort of 34 patients were enrolled.6 Further 
inclusion and exclusion criteria are outlined in Table 1. These patients were then randomized 
into either the ZR experimental group or PL control group using a randomized computer-
generated list created by an independent researcher.6 Patients were given identical packets 
containing indistinguishable products of either ZR or PL.6 Participants received a 30 day supply 
of their respective product and then underwent 15 days of wash out before receiving a 30 day 
supply of the other packet.6 Patients’ symptoms were evaluated before ingestion of either the ZR 
or PL packet at day zero and reassessed after 30 days of treatment for both legs of the study 
using the VAS.6  
Eleven subjects withdrew from the study for a final cohort of 23 participants for 
analysis.6 The ZR group showed a decreased level of patient reported bloating with a mean 
change from baseline of 60 ± 5 after 30 days of treatment (Table 3).6 The PL group mean change 
from baseline was higher at 77 ± 4 after 30 days of treatment (Table 3).6 Patients reported less 
bloating as a result of taking ZR compared to PL and a significant difference was noted with p = 
0.028 (Table 3).6 Patients were screened for adverse events each time they returned for 
evaluation, with no adverse effects reported.6 Compliance was assessed through returned, unused 
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product and compliance was considered acceptable for inclusion in the study if patients used 
more than 80% of the product they were given.6 This article did not address product tolerability.  
Table 3 – VAS symptom scores expressed as mean ± SD for control and experimental groups.6 
 Mean Change from Baseline P-value 
Experimental Group 60 ± 5 0.028* 
Control Group 77 ± 4 
* = Statistically significant (P < 0.05) 
 
 Almeida et al. is a case series comparing treatment of patients with a probiotic mixture of 
Lactobacillus casei Shirota and Bifidobacterium breve Yakult to their baseline.1 Patients were 
chosen by convenience sample of individuals attending the gastroenterology clinics affiliated 
with the university by which the researchers were employed.1 A total of 27 patients were 
enrolled based on a diagnosis of LI or LM established by a positive H2 breath test and associated 
gastrointestinal symptoms with lactose ingestion.1 Individuals with inflammatory bowel disease 
and prior gastrointestinal surgeries were excluded from the study.1 Additional inclusion and 
exclusion criteria are outlined in Table 1 above. Patients underwent assessment of symptoms at 
baseline before starting the probiotic treatment.1 Baseline mean score for flatulence and 
distension was reported as 2.1 ± 0.7 after a lactose challenge test (Table 4).1 After completion of 
the baseline test, all patients were instructed to start taking their probiotic the following day.1 
Patients were required to take the probiotic for 4 weeks, taking one packet at each meal for a 
total of three packets per day.1 At the conclusion of 4 weeks, patients symptoms were reassessed 
with a lactose challenge test, revealing a mean flatulence and distension score of 1.7 ± 1.2 after 
probiotic treatment (Table 4).1 The mean change from baseline after 4 weeks of probiotic 
treatment was calculated to be 0.4. (Table 4) This change in symptoms from baseline was not 
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found to be statistically significant with p > 0.5 (Table 4).1 No adverse effects were reported by 
patients after taking the probiotic mixture.1 This study did not assess tolerability or compliance. 
Table 4 – Symptom scores after lactose challenge expressed as mean ± SD for baseline and after 
4 weeks of probiotics1 




2.1 ± 0.7 1.7 ± 1.2 0.4 >0.05 
* = Statistically significant (P < 0.05) 
 
DISCUSSION: 
 Lactose intolerance has been shown to cause persistent gastrointestinal (GI) symptoms 
due to insufficient lactase activity.6 Lactic acid producing bacteria, such as Lactobacillus, are 
shown to convey increased lactase activity when ingested.7 Thus, treatment with probiotics has 
been suggested for these patients to increase functioning lactase, which enables them to digest 
milk products and lessen the symptoms they experience.7 This systematic review looked at the 
efficacy of Lactobacillus probiotics in improving symptoms of gas production, which included 
flatulence and distention or bloating. All studies recorded baseline and post-treatment symptom 
scores allowing comparison of the mean change from baseline to evaluate probiotic efficacy. 
Pakdaman et al. found a very small decrease in gas production compared to the placebo group 
without statistical significance.7 Similarly, Almeida et al. showed a decrease in gas production 
after probiotic use but the effect was small and not statistically significant.1 The Vitellio et al. 
study showed a decrease in gas production that was statistically significant, but this was similarly 
a small treatment effect when compared to the placebo group.6 Although each of the three 
articles showed some decrease in gas production symptoms, two out of three articles failed to 
show statistical significance in treatment efficacy.  
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There were limitations in each of the studies discussed in this review. These limitations 
were relatively uniform across each article, with the first being small sample size of between 20 
and 30 patients in their final cohorts.1, 6, 7 Additionally, all studies included treatment with 
probiotics for one month, either 30 days in Vitellio et al. or 4 weeks in both Pakdaman et al. and 
Almeida et al., which is a short period of time to realize the effects of the treatment.1, 6, 7  Both 
RTCs, Pakdaman et al. and Vitellio et al., mention the short duration of treatment as a limitation 
in their studies.6, 7 In contrast to these studies, the Almeida et al. study is a case-series and had no 
blinding.1 Because of this, all patients knew that they were receiving a probiotic, which has a 
potential to influence the patients’ responses when evaluated for symptomatic improvement.  
Additionally, there are limitations in this review itself as each study approached the 
measurement of symptoms differently. The breadth of the scale presented to patients affects how 
they rank their symptoms and disallows uniform comparison between studies. Vitellio et al. gave 
patients the largest range utilizing a VAS from 0 mm to 100 mm, Pakdaman et al. gave an 
intermediate range of 0-10, and Almeida et al. had the smallest range by giving patients the 
options of 0, 1, 2, or 3. 1, 6, 7 Because of their differing scales, the studies cannot be compared 
with one another by scale alone and each require interpretation of treatment effect individually. 
Another inconsistency amongst the articles includes the strain of Lactobaciullus and combination 
with other bacterium in the probiotics used. The different combinations and strains potentially 
cause varying effects on patients, which may make these studies nonuniform in comparison. 
There have been very few adverse effects associated with probiotic consumption.9 
However, the two most common adverse effects include flatulence and bloating.9 This may help 
to explain why the treatment effect from the probiotics was minimal at best in improving 
symptoms of gas production. Although lactase activity may have been improved and allowed for 
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more effective digestion of lactose, patients may be experiencing continued flatulence and 
distension from the probiotic treatment itself.9 However, the effects of bloating and flatulence 
have been found to wane with continued probiotic use.9 Because of this, studies should be 
conducted over a longer time period of time to allow for this effect to wane. In addition to these 
adverse effects, probiotics are not advised in patients that are critically ill or severely 
immunocompromised, as they are more susceptible to developing infection from the live 
bacterium found in probiotics.9  
CONCLUSION: 
 Although all studies showed a reduction in symptoms of gas production, treatment effects 
were very small and only one of the three studies showed statistical significance.1, 6, 7 Because of 
this, the evidence in this review is inconclusive about the efficacy of Lactobacillus in improving 
the symptoms of gas production. Further studies are needed to better answer the clinical 
question, which should include larger samples sizes.6, 7 Additionally, longer treatment with 
probiotics should be utilized in future studies. This would allow for initial adverse effects of the 
probiotics to normalize, as well as allow the probiotics to better colonize the gut flora.6, 7, 9 These 
studies should also compare the efficacy of probiotics to that of commercially available Lactaid 
supplements. Beyond this, a uniform measurement should be developed for evaluating patients 
with LI and their symptoms, which would allow for consistency when comparing the efficacy of 
different products for these patients. LI continues to affect a large percentage of the world’s 
population and products need to be developed that allow these individuals to continue lactose 
consumption, so that the nutrients of these products can be obtained without GI symptoms.3, 7 
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